Upstream Bio's future growth prospects are tied directly to the clinical development and commercialization of its core drug candidate, verekitug, which is undergoing advanced clinical trials for severe respiratory and inflammatory conditions like severe asthma and chronic rhinosinusitis. Biotech success depends heavily on upcoming trial data readouts and regulatory approvals.